In a tau-transgenic mouse model that displays late-stage pathology with a senescence-associated transcriptomic profile [122], dasatinib and quercetin (DQ) senolytic treatment for 12 weeks (two consecutive days every other week) significantly reduced NFT density, neuronal loss, and neurodegeneration, suggesting a strong association between cellular senescence and AD pathology [122]. The gene discussed is MAPT; the disease is Alzheimer disease.